Several reports have identified oncogenic mutations in MAPK kinase 1 (MAP2K1, also called MEK1) as alternative mechanism for MAPK pathway activation in BRAF wild-type tumor in various cancers (8–11). Here, MAP2K1 is linked to cancer.